VT Ablation in the iCMR
Key facts
- Where
- Amsterdam and The Hague, NetherlandsSee the 2 sites
Where in Netherlands
- Amsterdam UMCAmsterdam, NetherlandsContact: Michiel KemmeTaking people
- HagaZiekenhuisThe Hague, NetherlandsContact: Ivo Van Der Bilt, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Imricor Medical Systems
- Trial code
- NCT05543798
- Record updated
- 10 November 2026
- Original description
The VISABL-VT is a prospective, single-arm, multi-center, interventional investigation of the safety and efficacy of radiofrequency (RF) ablation of ventricular tachycardia associated with ischemic cardiomyopathy performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.Read full original descriptionShow less
Vision-MR Ablation Catheter 2.0 for the Treatment of Ventricular Tachycardia
The VISABL-VT is a prospective, single-arm, multi-center, interventional investigation of the safety and efficacy of radiofrequency (RF) ablation of ventricular tachycardia associated with ischemic cardiomyopathy performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.
Inclusion: Roll-in subjects only: Documentation of premature ventricular contractions indicated for ablation therapy (subjects may or may not be diagnosed with Ischemic Cardiomyopathy); Documented (ECG/EGM) spontaneous episode of sustained ventricular tachycardia within 6 months of the procedure; Diagnosis of Ischemic Cardiomyopathy; AAD therapy refractory, contraindicated, not tolerated, or not desired; 18 years or older.
Exclusion: Previous cardiac surgery within 60 days of procedures; Patients who do not tolerate anticoagulation therapy; Previous intertribal septal patch or prosthetic atrial septal defect closure device; Myocardial infarction requiring stent implantation within 90 days of procedure; Known/uncontrolled stroke risks; Class IV Heart Failure; Allergy to contrast agents (e.g., Gadolinium); Active infection; Unstable angina; Ejection Fraction (EF) < 25%; Patients with a glomerular filtration rate (GFR) < 30; Implanted with non-MR compatible medical devices or contraindicated for an MRI; Presence of intracardiac thrombus (verified via CT/MRI/TEE/TTE within 48 hours of procedure - or at start of procedure); Thrombocytopenia or coagulopathy; Mechanical mitral and/or aortic valve precluding access to the left ventricle; Severe aortic stenosis; Women who are pregnant; Known or suspected myxoma; Life expectancy < 12 months; Enrollment in another study without sponsor approval.